title: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence.
abstract: OBJECTIVE
  To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy.
  
  
  METHODS
  A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests.
  
  
  RESULTS
  With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8-10. The retrospective approach is a limitation of our study.
  
  
  CONCLUSIONS
  Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual's risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.
authors: Department of Urology, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany, alexander.karl@med.uni-muenchen.de.
authors: A
authors: A
authors: Karl
authors: A
authors: A
authors: Buchner
authors: C
authors: C
authors: Tympner
authors: T
authors: T
authors: Kirchner
authors: U
authors: U
authors: Ganswindt
authors: C
authors: C
authors: Belka
authors: R
authors: R
authors: Ganzer
authors: M
authors: M
authors: Burger
authors: F
authors: F
authors: Eder
authors: F
authors: F
authors: Hofstädter
authors: D
authors: D
authors: Schilling
authors: K
authors: K
authors: Sievert
authors: A
authors: A
authors: Stenzl
authors: M
authors: M
authors: Scharpf
authors: F
authors: F
authors: Fend
authors: F
authors: F
authors: Vom Dorp
authors: H
authors: H
authors: Rübben
authors: K
authors: K
authors: Schmid
authors: D
authors: D
authors: Porres-Knoblauch
authors: A
authors: A
authors: Heidenreich
authors: B
authors: B
authors: Hangarter
authors: R
authors: R
authors: Knüchel-Clarke
authors: M
authors: M
authors: Rogenhofer
authors: B
authors: B
authors: Wullich
authors: A
authors: A
authors: Hartmann
authors: E
authors: E
authors: Comploj
authors: A
authors: A
authors: Pycha
authors: E
authors: E
authors: Hanspeter
authors: D
authors: D
authors: Pehrke
authors: G
authors: G
authors: Sauter
authors: M
authors: M
authors: Graefen
authors: C
authors: C
authors: Stief
authors: A
authors: A
authors: Haese
mesh_terms: D000328:Adult; D000368:Aged; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis*; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen